Spac

Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases

Biotech SPAC deal merges Talawar Therapeutics with JATT II, aiming to disrupt eczema treatment with bispecifics